慢性阻塞性肺疾病痰白细胞介素-16的测定及其意义

收集１９例急性期慢性阻塞性肺疾病者,６例ＣＯＰＤ缓解期患者以及１０例正常对照者的痰液,以酶联免疫吸附法测定其痰液白细胞介素－１６水平,以探讨ＩＬ－１６在ＣＯＰＤ发病机制中的作用及其对ＣＯＰＤ气道为症的临床意义。结果,ＣＯＰＤ患者急性发作期痰ＩＬ－１６水平和缓解期均明显高于正常对照者。     

内镜辅助下完壁式鼓室成形术治疗慢性化脓性中耳炎疗效观察

目的探讨耳内镜辅助下完壁式乳突根治鼓室成形术治疗慢性化脓性中耳炎的临床效果和相关的经验教训。方法对56例(耳)慢性化脓性中耳炎患者实施耳内镜辅助下的完壁式乳突根治-鼓膜内植法修复鼓室成形术,术后进行言语频率(250~2000 Hz)气骨导差、声阻抗检查及临床效果观察。结果 56例(耳)患者均成功进行了手术,听力提高达91.8%;鼓膜有效达96.4%;干耳达94.6%。术后1年纯音测听示言语频率气骨导差:(17.5±8.1)d B H L;术后1年声阻抗:As型曲线29例,C型曲线10例,B型曲线17例。结论施行耳内镜辅助下完壁式乳突根治-鼓膜内植法修复鼓室成形术,既可以清除隐蔽部位病变组织,又可以有效保留原中耳乳突解剖结构和改善听力,更好地提高患者术后生活质量。常规手术加用耳内镜辅助治疗慢性化脓性中耳炎值得临床推广。     

解聚复肾宁对糖尿病大鼠肾脏HGF表达的影响

目的观察解聚复肾宁（JJFSN）对糖尿病大鼠肾HGF表达的影响及肾保护作用。方法SD大鼠腹腔注射链尿佐菌素法建立糖尿病模型,随机分为正常对照组、模型组、解聚复肾宁治疗组、依那普利治疗组、JJFSN＋依那普利治疗组。12周后,检测各组空腹血糖（FBG）、尿素（BU）、24h尿β2微球蛋白（β2-MG）、肌酐清除率（Ccr）;免疫组化法检测肾组织HGF表达,放射免疫法测定大鼠血清胰岛素（Ins）含量,透射电镜观察肾脏超微结构。结果与模型组比较,各治疗组大鼠FBG、BU、β2-MG明显降低,Ccr明显升高,血清Ins含量增加,肾组织HGF表达明显上调,肾组织病理变化减轻,其中以J＋Y组改善最显著（P〈0．05）。结论JJFSN对DM大鼠肾脏形态争功能有明显保护作用,其机制可能与其上调肾脏HGF表达、保护胰岛β细胞、延缓肾脏纤维化进程有关。     

T细胞介导炎症与血液肿瘤发生相关性研究进展

慢性炎症是肿瘤发生过程中一个重要因素,越来越多的研究显示T细胞介导炎症与多种肿瘤发生密切相关。本文主要综述近期有关T细胞介导炎症与血液肿瘤发生的相关性及其分子机制的新进展。     

糖尿病肾病的综合性防治

糖尿病(DM)是在遗传、自身免疫、环境因素作用下,胰岛素绝对或相对缺乏或胰岛素抵抗引起的以血糖升高为特点的一组代谢异常综合征,糖尿病肾病(DN)是DM常见而严重的微血管并发症之一,是DM主要死因之一,因此,有效防治DN的发生和发展是一项重要任务,需采取综合性防治措施.     

慢性心力衰竭兔心室结构重构对心电生理功能产生的影响及意义

目的 探讨慢性心力衰竭(CHF)兔心室结构重构对心电生理功能的影响及意义.方法 雄性新西兰兔32只,随机分为对照组(n=15)和CHF组(n=17),CHF组采用经兔耳静脉注射异丙肾上腺素(ISO)制备CHF模型,最终造模成功15只.对照组给予相同体积的0.9％生理盐水,最终12只进入实验.采用超声心动图监测两组兔M型...     

Activation of cytotoxic T cells by solid tumours?

Tumour-specific cytotoxic T cells (CTLs) are among the best-defined biological anticancer weapons. Nevertheless, they often fail to control tumour growth in vivo. Many reasons for this have been evoked tumours may actively inhibit CTLs, or may protect them selves from CTL recognition by various means. However, one does not necessarily need to postulate such active immune evasion mechanisms specifically acquired by tumour cells. In this review we argue that the failure of immune protection is due to the intrinsic inability of tumours to activate an effective immune response, and that many tumours are similar to normal issues in this respect. It is striking to see that the majority of the so-called immune escape mechanisms are not specifically acquired by selected tumour cells, but are common mechanisms shared between solid tumours and normal, healthy tissues. Immune responses are poor because tumour antigens do not efficiently localize to lymph follicles in lymphoid tissues, and are not efficiently presented to CTLs in an immunogenic context. The fact that tumours do not induce CTLs but are often susceptible to lymphocyte-mediated cytotoxicity indicates that more intensified immunization protocols should result in improved clinical outcome.     

丹参川芎嗪治疗早期糖尿病肾病临床效果及对炎性因子影响

目的 探讨丹参川穹嗪对早期糖尿病肾病的临床治疗效果及对患者体内炎性因子的影响.方法 选取87例早期糖尿病肾病患者为研究对象,将其按照不同治疗方法分为对照组和研究组,对照组44例,采用常规方法治疗;研究组43例,在对照组基础上添加丹参川穹嗪进行治疗,观察两组患者治疗的总有效率及不良反应发生率,并将两组患者的UAER,UACR,β2-MG及血清IL-6,IL-18,TNF-α进行观察和比较.结果 对照组患者总有效率及不良反应发生率分别为78.57%和23.81%;治疗后UAER,UACR,β2-MG分别为(110.31±19.27)mg/d,(81.46±9.46)mg/g,(17.69±4.68)mg/L;血清IL-6,IL-18,TNF-α分别为(12.13±2.10),(135.21±37.23),(39.21±11.25)mg/L.研究组患者总有效率及不良反应发生率分别为95.12%,4.88%;治疗后UAER,UACR,β2-MG分别为(92.16±21.39)mg/d,(67.14±8.15)mg/g,(13.62±4.21)mg/L;血清IL-6,IL-18,TNF-α分别为(8.05±2.01),(103.26±32.85),(23.68±11.84)mg/L.两组间各数据比较差异具有统计学意义(P<0.05).结论 丹参川穹嗪在早期糖尿病肾病的治疗中能够有效降低患者体内炎性因子水平.     

运动疗法对慢性下腰痛的康复研究

目的:探讨运动疗法对慢性下腰痛的康复功效;方法:采用文献资料法、实验法以及数理统计法进行研究;将符合本实验纳入标准和排除标准的18例慢性下腰痛患者,进行为期一个月的运动疗法治疗;结果:18例患者腰部疼痛度明显减轻,VAS实验前后数据成显著性差异(P0.01);腰部活动度得到改善(P0.01);腰部肌肉力量增长(P0.01);本体感觉偏离度改善较小(P0.01);结论:运动疗法对下腰痛有显著疗效。     

The innate immunity of the central nervous system in chronic pain: The role of Toll-like receptors

Toll-like receptors (TLRs) are a family of pattern recognition receptors that mediate innate immune responses to stimuli from pathogens or endogenous signals. Under various pathological conditions, the central nervous system (CNS) mounts a well-organized innate immune response, in which glial cells, in particular microglia, are activated. Further, the innate immune system has emerged as a promising target for therapeutic control of development and persistence of chronic pain. Especially, microglial cells respond to peripheral and central infection, injury, and other stressor signals arriving at the CNS and initiate a CNS immune activation that might contribute to chronic pain facilitation. In the orchestration of this limited immune reaction, TLRs on microglia appear to be most relevant in triggering and tailoring microglial activation, which might be a driving force of chronic pain. New therapeutic approaches targeting the CNS innate immune system may achieve the essential pharmacological control of chronic pain. Received 21 November 2006; received after revision 8 January 2007; accepted 7 February 2007